296
Participants
Start Date
March 31, 2005
Primary Completion Date
February 28, 2007
Study Completion Date
February 28, 2007
Aripiprazole
Treatment Arm 1 (10 mg treatment arm): Aripiprazole 2 mg QD for 2 days, aripiprazole 5 mg QD for 2 days, and aripiprazole 10 mg QD as the target dose starting on Day 5. Subjects remained on the 10 mg dose for the remainder of the treatment period Subjects reached their target dose through a forced titration schedule and proceeded with treatment at their target dose until Week 4. If the subject reached Week 4, he or she continued into the Extension Phase, a 6-month double-blind treatment period, beginning at the same dose taken at the end of the Acute Phase.
Aripiprazole
Treatment Arm 2 (30 mg treatment arm): Aripiprazole 2 mg QD for 2 days, aripiprazole 5 mg QD for 2 days, aripiprazole 10 mg QD for 2 days, aripiprazole 15 mg QD for 2 days, aripiprazole 20 mg QD for 2 days, aripiprazole 25 mg QD for 2 days, and aripiprazole 30 mg QD as the target dose starting on Day 13. Subjects remained on the 30 mg dose for the remainder of the treatment period. Subjects reached their target dose through a forced titration schedule and proceeded with treatment at their target dose until Week 4. If the subject reached Week 4, he or she continued into the Extension Phase, a 6-month double-blind treatment period, beginning at the same dose taken at the end of the Acute Phase.
placebo
Placebo tablet
Local Institution, Scottsdale
Local Institution, Little Rock
Local Institution, National City
Local Institution, Orange
Local Institution, Pasadena
Local Institution, Sacramento
Local Institution, San Diego
Local Institution, Stanford
Local Institution, Washington D.C.
Local Institution, Altamonte Springs
Local Institution, Hialeah
Local Institution, Jacksonville
Local Institution, Miami
Local Institution, North Miami
Local Institution, Tampa
Local Institution, Atlanta
Local Institution, Smyrna
Local Institution, Boise
Local Institution, Chicago
Local Institution, Libertyville
Local Institution, Indianapolis
Local Institution, Kansas City
Local Institution, Newton
Local Institution, Lexington
Local Institution, Baton Rouge
Local Institution, Lake Charles
Local Institution, Shreveport
Local Institution, Cambridge
Local Institution, Medford
Local Institution, Clinton Township
Local Institution, Rochester Hills
Local Institution, Kansas City
Local Institution, St Louis
Local Institution, Las Vegas
Local Institution, Elmsford
Local Institution, New York
Local Institution, Rochester
Local Institution, Stony Brook
Local Institution, Cincinnati
Local Institution, Cleveland
Local Institution, Oklahoma City
Local Institution, Philadelphia
Local Institution, Charleston
Local Institution, Memphis
Local Institution, Bellaire
Local Institution, Fort Worth
Local Institution, Houston
Local Institution, San Antonio
Local Institution, Herndon
Local Institution, Richmond
Local Institution, Kirkland
Local Institution, Spokane
Local Institution, Milwaukee
Otsuka Pharmaceutical Development & Commercialization, Inc.
INDUSTRY